The Biden administration proposes covering weight-loss medications for individuals under Medicare and Medicaid, potentially impacting obesity treatment funding. The U.S. Department of Health and Human Services anticipates costs of up to $35 billion over the next decade. Secretary Xavier Becerra emphasizes benefits for those unable to afford these medications. The proposed rule awaits finalization in January and aims to classify obesity as a treatable disease. Individuals classified as obese, with a body mass index of 30 or above, would be eligible for the coverage. Approximately 3.5 million Medicare recipients and 4 million Medicaid beneficiaries could gain access, with an estimated 28 million individuals on Medicaid classified as obese. While FDA-approved anti-obesity drugs can help patients lose significant weight, high costs and supply shortages limit access. Robert F. Kennedy Jr. opposes the use of these medications, advocating for investments in nutrition and physical fitness instead. Learn more on this news visit us at: https://greyjournal.net/ Hosted on Acast. See acast.com/privacy for more information.